{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:36:46Z","timestamp":1772750206032,"version":"3.50.1"},"reference-count":240,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["IF\/00578\/2014"],"award-info":[{"award-number":["IF\/00578\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Centro 2020 Regional Operational Programme","doi-asserted-by":"publisher","award":["CENTRO-01-0145-FEDER-000008"],"award-info":[{"award-number":["CENTRO-01-0145-FEDER-000008"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-007440"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007440"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["FCTSFRH\/BPD\/97650\/2013"],"award-info":[{"award-number":["FCTSFRH\/BPD\/97650\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/04349\/2013"],"award-info":[{"award-number":["UID\/Multi\/04349\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,3,16]]},"abstract":"<jats:sec><jats:title\/><jats:p>Paediatric Acquired ImmunoDeficiency Syndrome (AIDS) is a life-threatening and infectious disease in which the Human Immunodeficiency Virus (HIV) is mainly transmitted through Mother-To- Child Transmission (MTCT) during pregnancy, labour and delivery, or breastfeeding. This review provides an overview of the distinct therapeutic alternatives to abolish the systemic viral replication in paediatric HIV-1 infection. Numerous classes of antiretroviral agents have emerged as therapeutic tools for downregulation of different steps in the HIV replication process. These classes encompass Non- Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs), Nucleoside\/Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs\/NtRTIs), INtegrase Inhibitors (INIs), Protease Inhibitors (PIs), and Entry Inhibitors (EIs). Co-administration of certain antiretroviral drugs with Pharmacokinetic Enhancers (PEs) may boost the effectiveness of the primary therapeutic agent. The combination of multiple antiretroviral drug regimens (Highly Active AntiRetroviral Therapy - HAART) is currently the standard therapeutic approach for HIV infection. So far, the use of HAART offers the best opportunity for prolonged and maximal viral suppression, and preservation of the immune system upon HIV infection. Still, the frequent administration of high doses of multiple drugs, their inefficient ability to reach the viral reservoirs in adequate doses, the development of drug resistance, and the lack of patient compliance compromise the complete HIV elimination. The development of nanotechnology-based drug delivery systems may enable targeted delivery of antiretroviral agents to inaccessible viral reservoir sites at therapeutic concentrations. In addition, the application of Computer-Aided Drug Design (CADD) approaches has provided valuable tools for the development of anti-HIV drug candidates with favourable pharmacodynamics and pharmacokinetic properties.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867325666180904123549","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T04:45:47Z","timestamp":1536641147000},"page":"760-794","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An Overview of Antiretroviral Agents for Treating HIV Infection in Paediatric Population"],"prefix":"10.2174","volume":"27","author":[{"given":"Rita","family":"Melo","sequence":"first","affiliation":[{"name":"Centro de Ciencias e Tecnologias Nucleares, Instituto Superior Tecnico, Universidade de Lisboa, CTN, Estrada Nacional 10 (km 139,7), Bobadela LRS 2695-066, Portugal"}]},{"given":"Agostinho","family":"Lemos","sequence":"additional","affiliation":[{"name":"CNC - Center for Neuroscience and Cell Biology; Rua Larga, FMUC, Polo I, 1\u00baandar, Universidade de Coimbra, Coimbra 3004-517, Portugal"}]},{"given":"Ant\u00f3nio J.","family":"Preto","sequence":"additional","affiliation":[{"name":"CNC - Center for Neuroscience and Cell Biology; Rua Larga, FMUC, Polo I, 1\u00baandar, Universidade de Coimbra, Coimbra 3004-517, Portugal"}]},{"given":"Beatriz","family":"Bueschbell","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry I, PharmaCenter, Pharmaceutical Institute, University of Bonn, Bonn, Germany"}]},{"given":"Pedro","family":"Matos-Filipe","sequence":"additional","affiliation":[{"name":"CNC - Center for Neuroscience and Cell Biology; Rua Larga, FMUC, Polo I, 1\u00baandar, Universidade de Coimbra, Coimbra 3004-517, Portugal"}]},{"given":"Carlos","family":"Barreto","sequence":"additional","affiliation":[{"name":"CNC - Center for Neuroscience and Cell Biology; Rua Larga, FMUC, Polo I, 1\u00baandar, Universidade de Coimbra, Coimbra 3004-517, Portugal"}]},{"given":"Jos\u00e9 G.","family":"Almeida","sequence":"additional","affiliation":[{"name":"CNC - Center for Neuroscience and Cell Biology; Rua Larga, FMUC, Polo I, 1\u00baandar, Universidade de Coimbra, Coimbra 3004-517, Portugal"}]},{"given":"R\u00faben D.M.","family":"Silva","sequence":"additional","affiliation":[{"name":"Centro de Ciencias e Tecnologias Nucleares, Instituto Superior Tecnico, Universidade de Lisboa, CTN, Estrada Nacional 10 (km 139,7), Bobadela LRS 2695-066, Portugal"}]},{"given":"Jo\u00e3o D.G.","family":"Correia","sequence":"additional","affiliation":[{"name":"Centro de Ciencias e Tecnologias Nucleares, Instituto Superior Tecnico, Universidade de Lisboa, CTN, Estrada Nacional 10 (km 139,7), Bobadela LRS 2695-066, Portugal"}]},{"given":"Irina S.","family":"Moreira","sequence":"additional","affiliation":[{"name":"CNC - Center for Neuroscience and Cell Biology; Rua Larga, FMUC, Polo I, 1\u00baandar, Universidade de Coimbra, Coimbra 3004-517, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"665","volume":"31","year":"1982","unstructured":"Unexplained immunodeficiency and opportunistic infections in infants-New York, New Jersey, California. MMWR Morb Mortal Wkly Rep Centers for Disease Control (CDC)1982,31(49),665-667","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=2","year":"2017","unstructured":"UNAIDS. World AIDS Day Available at:(Accessed: June 25, 2018)2017","journal-title":"World AIDS Day"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/oxfordjournals.epirev.a017922","volume":"18","author":"John G.C.","year":"1996","unstructured":"John G.C.; Kreiss J.; Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev 1996,18(2),149-157","journal-title":"Epidemiol Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imr.12074","volume":"254","author":"Tobin N.H.","year":"2013","unstructured":"Tobin N.H.; Aldrovandi G.M.; Immunology of pediatric HIV infection. Immunol Rev 2013,254(1),143-169","journal-title":"Immunol Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1742-6405-4-11","volume":"4","author":"Langford S.E.","year":"2007","unstructured":"Langford S.E.; Ananworanich J.; Cooper D.A.; Predictors of disease progression in HIV infection: a review. AIDS Res Ther 2007,4(1),11","journal-title":"AIDS Res Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S1045-1870(05)80018-4","volume":"6","author":"Van Dyke R.B.","year":"1995","unstructured":"Van Dyke R.B.; Opportunistic infections in HIV-infected children. Semin Pediatr Infect Dis 1995,6(1),10-16","journal-title":"Semin Pediatr Infect Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10461-016-1670-9","volume":"21","author":"Idele P.","year":"2017","unstructured":"Idele P.; Hayashi C.; Porth T.; Mamahit A.; Mahy M.; Prevention of mother-to-child transmission of HIV and paediatric HIV care and treatment monitoring: from measuring process to impact and elimination of mother-to-child transmission of HIV. AIDS Behav 2017,21(1)(Suppl. 1),23-33","journal-title":"AIDS Behav"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(06)69157-5","volume":"368","author":"Simon V.","year":"2006","unstructured":"Simon V.; Ho D.D.; Abdool Karim Q.; HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006,368(9534),489-504","journal-title":"Lancet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jmb.2011.04.029","volume":"410","author":"Lu K.","year":"2011","unstructured":"Lu K.; Heng X.; Summers M.F.; Structural determinants and mechanism of HIV-1 genome packaging. J Mol Biol 2011,410(4),609-633","journal-title":"J Mol Biol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000445852","volume":"43","year":"2016","unstructured":"Subgroup \u2018Assessment of Pathogens Transmissible by Blood\u2019. Human immunodeficiency virus (HIV). Transfus Med Hemother German Advisory Committee Blood (Arbeitskreis Blut)2016,43(3),203-222","journal-title":"Transfus Med Hemother"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1096\/fasebj.5.10.1829694","volume":"5","author":"Haseltine W.A.","year":"1991","unstructured":"Haseltine W.A.; Molecular biology of the human immunodeficiency virus type 1. FASEB J 1991,5(10),2349-2360","journal-title":"FASEB J"},{"key":"ref=12","first-page":"210","volume":"7","author":"Thomson M.M.","year":"2005","unstructured":"Thomson M.M.; N\u00e1jera R.; Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev 2005,7(4),210-224","journal-title":"AIDS Rev"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006841","volume":"1","author":"Sharp P.M.","year":"2011","unstructured":"Sharp P.M.; Hahn B.H.; Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011,1(1)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1172\/JCI34706","volume":"118","author":"Cohen M.S.","year":"2008","unstructured":"Cohen M.S.; Hellmann N.; Levy J.A.; DeCock K.; Lange J.; The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008,118(4),1244-1254","journal-title":"J Clin Invest"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/cid\/ciq248","volume":"52","author":"Campbell-Yesufu O.T.","year":"2011","unstructured":"Campbell-Yesufu O.T.; Gandhi R.T.; Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011,52(6),780-787","journal-title":"Clin Infect Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/rmv.1739","volume":"23","author":"Nyamweya S.","year":"2013","unstructured":"Nyamweya S.; Hegedus A.; Jaye A.; Rowland-Jones S.; Flanagan K.L.; Macallan D.C.; Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis. Rev Med Virol 2013,23(4),221-240","journal-title":"Rev Med Virol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"9380","DOI":"10.1073\/pnas.142287999","volume":"99","author":"Cicala C.","year":"2002","unstructured":"Cicala C.; Arthos J.; Selig S.M.; Dennis G.; Hosack D.A.; Van Ryk D.; Spangler M.L.; Steenbeke T.D.; Khazanie P.; Gupta N.; Yang J.; Daucher M.; Lempicki R.A.; Fauci A.S.; HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci USA 2002,99(14),9380-9385","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.4049\/jimmunol.173.12.7150","volume":"173","author":"Balabanian K.","year":"2004","unstructured":"Balabanian K.; Harriague J.; D\u00e9crion C.; Lagane B.; Shorte S.; Baleux F.; Virelizier J.L.; Arenzana-Seisdedos F.; Chakrabarti L.A.; CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. J Immunol 2004,173(12),7150-7160","journal-title":"J Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1146\/annurev.immunol.17.1.625","volume":"17","author":"Haase A.T.","year":"1999","unstructured":"Haase A.T.; Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999,17(1),625-656","journal-title":"Annu Rev Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","volume":"70","author":"Eckert D.M.","year":"2001","unstructured":"Eckert D.M.; Kim P.S.; Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001,70,777-810","journal-title":"Annu Rev Biochem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1007\/s00018-008-8147-6","volume":"65","author":"Garg H.","year":"2008","unstructured":"Garg H.; Blumenthal R.; Role of HIV Gp41 mediated fusion\/hemifusion in bystander apoptosis. Cell Mol Life Sci 2008,65(20),3134-3144","journal-title":"Cell Mol Life Sci"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006866","volume":"2","author":"Wilen C.B.","year":"2012","unstructured":"Wilen C.B.; Tilton J.C.; Doms R.W.; HIV: cell binding and entry. Cold Spring Harb Perspect Med 2012,2(8)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/v2020606","volume":"2","author":"Singh K.","year":"2010","unstructured":"Singh K.; Marchand B.; Kirby K.A.; Michailidis E.; Sarafianos S.G.; Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses 2010,2(2),606-638","journal-title":"Viruses"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006882","volume":"2","author":"Hu W.S.","year":"2012","unstructured":"Hu W.S.; Hughes S.H.; HIV-1 reverse transcription. Cold Spring Harb Perspect Med 2012,2(10)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nrd1660","volume":"4","author":"Pommier Y.","year":"2005","unstructured":"Pommier Y.; Johnson A.A.; Marchand C.; Integrase inhibitors to treat HIV\/AIDS. Nat Rev Drug Discov 2005,4(3),236-248","journal-title":"Nat Rev Drug Discov"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006890","volume":"2","author":"Craigie R.","year":"2012","unstructured":"Craigie R.; Bushman F.D.; HIV DNA integration. Cold Spring Harb Perspect Med 2012,2(7)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2217\/fvl.12.56","volume":"7","author":"Craigie R.","year":"2012","unstructured":"Craigie R.; The molecular biology of HIV integrase. Future Virol 2012,7(7),679-686","journal-title":"Future Virol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"8527","DOI":"10.1128\/JVI.73.10.8527-8540.1999","volume":"73","author":"Burniston M.T.","year":"1999","unstructured":"Burniston M.T.; Cimarelli A.; Colgan J.; Curtis S.P.; Luban J.; Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J Virol 1999,73(10),8527-8540","journal-title":"J Virol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1039\/b208248a","volume":"1","author":"Brik A.","year":"2003","unstructured":"Brik A.; Wong C-H.; HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 2003,1(1),5-14","journal-title":"Org Biomol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"Cihlar T.","year":"2016","unstructured":"Cihlar T.; Fordyce M.; Current status and prospects of HIV treatment. Curr Opin Virol 2016,18,50-56","journal-title":"Curr Opin Virol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jcv.2005.09.004","volume":"34","author":"Sierra S.","year":"2005","unstructured":"Sierra S.; Kupfer B.; Kaiser R.; Basics of the virology of HIV-1 and its replication. J Clin Virol 2005,34(4),233-244","journal-title":"J Clin Virol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"Palella F.J.J.","year":"1998","unstructured":"Palella F.J.J.; Delaney K.M.; Moorman A.C.; Loveless M.O.; Fuhrer J.; Satten G.A.; Aschman D.J.; Holmberg S.D.; Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med HIV Outpatient Study Investigators1998,338(13),853-860","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1086\/314623","volume":"179","author":"Vittinghoff E.","year":"1999","unstructured":"Vittinghoff E.; Scheer S.; O\u2019Malley P.; Colfax G.; Holmberg S.D.; Buchbinder S.P.; Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999,179(3),717-720","journal-title":"J Infect Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","volume":"352","author":"Mocroft A.","year":"1998","unstructured":"Mocroft A.; Vella S.; Benfield T.L.; Chiesi A.; Miller V.; Gargalianos P.; d\u2019Arminio Monforte A.; Yust I.; Bruun J.N.; Phillips A.N.; Lundgren J.D.; Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998,352(9142),1725-1730","journal-title":"Lancet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJM198707233170401","volume":"317","author":"Fischl M.A.","year":"1987","unstructured":"Fischl M.A.; Richman D.D.; Grieco M.H.; Gottlieb M.S.; Volberding P.A.; Laskin O.L.; Leedom J.M.; Groopman J.E.; Mildvan D.; Schooley R.T.; Jackson G.G.; Durack D.T.; King D.; The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987,317(4),185-191","journal-title":"N Engl J Med"},{"key":"ref=36","first-page":"242","volume":"103","author":"Young F.E.","year":"1988","unstructured":"Young F.E.; The role of the FDA in the effort against AIDS. Public Health Rep 1988,103(3),242-245","journal-title":"Public Health Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2174\/1570162X15666171120110145","volume":"15","author":"Holec A.D.","year":"2017","unstructured":"Holec A.D.; Mandal S.; Prathipati P.K.; Destache C.J.; Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV Therapeutics. Curr HIV Res 2017,15(6),411-421","journal-title":"Curr HIV Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1093\/emboj\/cdf637","volume":"21","author":"Sarafianos S.G.","year":"2002","unstructured":"Sarafianos S.G.; Clark A.D.; Das K.; Tuske S.; Birktoft J.J.; Ilankumaran P.; Ramesha A.R.; Sayer J.M.; Jerina D.M.; Boyer P.L.; Hughes S.H.; Arnold E.; Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J 2002,21(23),6614-6624","journal-title":"EMBO J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nsmb760","volume":"11","author":"Tuske S.","year":"2004","unstructured":"Tuske S.; Sarafianos S.G.; Clark A.D.; Ding J.; Naeger L.K.; White K.L.; Miller M.D.; Gibbs C.S.; Boyer P.L.; Clark P.; Wang G.; Gaffney B.L.; Jones R.A.; Jerina D.M.; Hughes S.H.; Arnold E.; Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol 2004,11(5),469-474","journal-title":"Nat Struct Mol Biol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3851\/IMP1716","volume":"21","author":"Rhodes D.I.","year":"2011","unstructured":"Rhodes D.I.; Peat T.S.; Vandegraaff N.; Jeevarajah D.; Le G.; Jones E.D.; Smith J.A.; Coates J.A.; Winfield L.J.; Thienthong N.; Newman J.; Lucent D.; Ryan J.H.; Savage G.P.; Francis C.L.; Deadman J.J.; Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design. Antivir Chem Chemother 2011,21(4),155-168","journal-title":"Antivir Chem Chemother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","volume":"85","author":"de B\u00e9thune M-P.","year":"2010","unstructured":"de B\u00e9thune M-P.; Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 2010,85(1),75-90","journal-title":"Antiviral Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1126\/science.1377403","volume":"256","author":"Kohlstaedt L.A.","year":"1992","unstructured":"Kohlstaedt L.A.; Wang J.; Friedman J.M.; Rice P.A.; Steitz T.A.; Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992,256(5065),1783-1790","journal-title":"Science"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1126\/science.7532321","volume":"267","author":"Spence R.A.","year":"1995","unstructured":"Spence R.A.; Kati W.M.; Anderson K.S.; Johnson K.A.; Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995,267(5200),988-993","journal-title":"Science"},{"key":"ref=44","volume":"27","author":"Ren J.","year":"2020","unstructured":"Ren J.; Milton J.; Weaver K.L.; Short S.A.; Stuart D.I.; Stammers D.K.; Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure, 2000, 8(10), 1089-1094. 26. Curr Med Chem [Melo et al.].2020,27(00)","journal-title":"Curr Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1046\/j.1432-1327.2002.02811.x","volume":"269","author":"Lindberg J.","year":"2002","unstructured":"Lindberg J.; Sigurdsson S.; L\u00f6wgren S.; Andersson H.O.; Sahlberg C.; Nor\u00e9en R.; Fridborg K.; Zhang H.; Unge T.; Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 2002,269(6),1670-1677","journal-title":"Eur J Biochem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1021\/jm1002233","volume":"53","author":"Lansdon E.B.","year":"2010","unstructured":"Lansdon E.B.; Brendza K.M.; Hung M.; Wang R.; Mukund S.; Jin D.; Birkus G.; Kutty N.; Liu X.; Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem 2010,53(10),4295-4299","journal-title":"J Med Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2047-783X-14-S3-5","volume":"14","author":"Mouscadet J-F.","year":"2009","unstructured":"Mouscadet J-F.; Tchertanov L.; Raltegravir: molecular basis of its mechanism of action. Eur J Med Res 2009,14(Suppl. 3),5-16","journal-title":"Eur J Med Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1073\/pnas.092056199","volume":"99","author":"Grobler J.A.","year":"2002","unstructured":"Grobler J.A.; Stillmock K.; Hu B.; Witmer M.; Felock P.; Espeseth A.S.; Wolfe A.; Egbertson M.; Bourgeois M.; Melamed J.; Wai J.S.; Young S.; Vacca J.; Hazuda D.J.; Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002,99(10),6661-6666","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40262-014-0167-9","volume":"53","author":"Larson K.B.","year":"2014","unstructured":"Larson K.B.; Wang K.; Delille C.; Otofokun I.; Acosta E.P.; Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet 2014,53(10),865-872","journal-title":"Clin Pharmacokinet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1021\/bi051886s","volume":"45","author":"Clemente J.C.","year":"2006","unstructured":"Clemente J.C.; Coman R.M.; Thiaville M.M.; Janka L.K.; Jeung J.A.; Nukoolkarn S.; Govindasamy L.; Agbandje-McKenna M.; McKenna R.; Leelamanit W.; Goodenow M.M.; Dunn B.M.; Analysis of HIV-1 CRF_01 A\/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry 2006,45(17),5468-5477","journal-title":"Biochemistry"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1128\/AAC.00868-13","volume":"57","author":"Yedidi R.S.","year":"2013","unstructured":"Yedidi R.S.; Maeda K.; Fyvie W.S.; Steffey M.; Davis D.A.; Palmer I.; Aoki M.; Kaufman J.D.; Stahl S.J.; Garimella H.; Das D.; Wingfield P.T.; Ghosh A.K.; Mitsuya H.; P2\u2032 benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety. Antimicrob Agents Chemother 2013,57(10),4920-4927","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1021\/ja00108a056","volume":"117","author":"Kim E.","year":"1995","unstructured":"Kim E.; Baker C.; Dwyer M.; Murcko M.; Rao B.; Tung R.; Navia M.; Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 1995,117(3),1181-1182","journal-title":"J Am Chem Soc"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1111\/j.1742-4658.2010.07771.x","volume":"277","author":"Shen C.H.","year":"2010","unstructured":"Shen C.H.; Wang Y.F.; Kovalevsky A.Y.; Harrison R.W.; Weber I.T.; Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J 2010,277(18),3699-3714","journal-title":"FEBS J"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/S0968-0896(02)00051-2","volume":"10","author":"Stoll V.","year":"2002","unstructured":"Stoll V.; Qin W.; Stewart K.D.; Jakob C.; Park C.; Walter K.; Simmer R.L.; Helfrich R.; Bussiere D.; Kao J.; Kempf D.; Sham H.L.; Norbeck D.W.; X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg Med Chem 2002,10(8),2803-2806","journal-title":"Bioorg Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1021\/jm070284z","volume":"50","author":"Reddy G.S.","year":"2007","unstructured":"Reddy G.S.; Ali A.; Nalam M.N.; Anjum S.G.; Cao H.; Nathans R.S.; Schiffer C.A.; Rana T.M.; Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2\/P2\u2032 ligands in pseudosymmetric dipeptide isosteres. J Med Chem 2007,50(18),4316-4328","journal-title":"J Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1021\/jm9704098","volume":"40","author":"Kaldor S.W.","year":"1997","unstructured":"Kaldor S.W.; Kalish V.J.; Davies J.F.; Shetty B.V.; Fritz J.E.; Appelt K.; Burgess J.A.; Campanale K.M.; Chirgadze N.Y.; Clawson D.K.; Dressman B.A.; Hatch S.D.; Khalil D.A.; Kosa M.B.; Lubbehusen P.P.; Muesing M.A.; Patick A.K.; Reich S.H.; Su K.S.; Tatlock J.H.; Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997,40(24),3979-3985","journal-title":"J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/med.20138","volume":"29","author":"Qian K.","year":"2009","unstructured":"Qian K.; Morris-Natschke S.L.; Lee K-H.; HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 2009,29(2),369-393","journal-title":"Med Res Rev"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/jac\/dkl027","volume":"57","author":"Briz V.","year":"2006","unstructured":"Briz V.; Poveda E.; Soriano V.; HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006,57(4),619-627","journal-title":"J Antimicrob Chemother"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1517\/13543784.11.12.1837","volume":"11","author":"Chen R.Y.","year":"2002","unstructured":"Chen R.Y.; Kilby J.M.; Saag M.S.; Enfuvirtide. Expert Opin Investig Drugs 2002,11(12),1837-1843","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.1241475","volume":"341","author":"Tan Q.","year":"2013","unstructured":"Tan Q.; Zhu Y.; Li J.; Chen Z.; Han G.W.; Kufareva I.; Li T.; Ma L.; Fenalti G.; Li J.; Zhang W.; Xie X.; Yang H.; Jiang H.; Cherezov V.; Liu H.; Stevens R.C.; Zhao Q.; Wu B.; Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 2013,341(6152),1387-1390","journal-title":"Science"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/ml1000257","volume":"1","author":"Xu L.","year":"2010","unstructured":"Xu L.; Liu H.; Murray B.P.; Callebaut C.; Lee M.S.; Hong A.; Strickley R.G.; Tsai L.K.; Stray K.M.; Wang Y.; Rhodes G.R.; Desai M.C.; Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett 2010,1(5),209-213","journal-title":"ACS Med Chem Lett"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","volume":"37","author":"Sherman E.M.","year":"2015","unstructured":"Sherman E.M.; Worley M.V.; Unger N.R.; Gauthier T.P.; Schafer J.J.; Cobicistat: review of a pharmacokinetic enhancer for HIV infection. Clin Ther 2015,37(9),1876-1893","journal-title":"Clin Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"18422","DOI":"10.1073\/pnas.1010693107","volume":"107","author":"Sevrioukova I.F.","year":"2010","unstructured":"Sevrioukova I.F.; Poulos T.L.; Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA 2010,107(43),18422-18427","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=64","unstructured":"AIDS info: Offering information on HIV\/AIDS treatment, prevention, and research Available at:(Accessed: June 25, 2018).","journal-title":"AIDS info: Offering information on HIV\/AIDS treatment, prevention, and research"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/QAD.0b013e3283324283","volume":"24","author":"Ray M.","year":"2010","unstructured":"Ray M.; Logan R.; Sterne J.A.; Hern\u00e1ndez-D\u00edaz S.; Robins J.M.; Sabin C.; Bansi L.; van Sighem A.; de Wolf F.; Costagliola D.; Lanoy E.; Bucher H.C.; von Wyl V.; Esteve A.; Casbona J.; del Amo J.; Moreno S.; Justice A.; Goulet J.; Lodi S.; Phillips A.; Seng R.; Meyer L.; P\u00e9rez-Hoyos S.; Garc\u00eda de Olalla P.; Hern\u00e1n M.A.; The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS HIV-CAUSAL Collaboration2010,24(1),123-137","journal-title":"AIDS"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1128\/AAC.00976-10","volume":"55","author":"Pirrone V.","year":"2011","unstructured":"Pirrone V.; Thakkar N.; Jacobson J.M.; Wigdahl B.; Krebs F.C.; Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother 2011,55(5),1831-1842","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/0253-7613.96296","volume":"44","author":"Desai M.","year":"2012","unstructured":"Desai M.; Iyer G.; Dikshit R.K.; Antiretroviral drugs: critical issues and recent advances. Indian J Pharmacol 2012,44(3),288-298","journal-title":"Indian J Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jama.284.2.190","volume":"284","author":"de Martino M.","year":"2000","unstructured":"de Martino M.; Tovo P.A.; Balducci M.; Galli L.; Gabiano C.; Rezza G.; Pezzotti P.; Osimani P.; Di Bari C.; Larovere D.; Ruggeri M.; Masi M.; Specchia F.; Battisti L.; Duse M.; Crispino P.; Carrara P.; Pintor C.; Dedoni M.; Dess\u00ec C.; Loriano D.; Anastasio E.; Bezzi T.; De Luca M.; Farina S.; Vierucci A.; Bassetti D.; Pontali E.; Boni S.; Marazzi M.G.; Tasso L.; Giovanettoni C.; Salvini F.; Pinzani R.; Marchisio P.; Vigan\u00f2 A.; Tornaghi R.; Zuccotti G.V.; Riva E.; Giovannini M.; Lipreri R.; Conio S.; Ferraris G.; Cellini M.; Baraldi C.; Guarino A.; Canani R.B.; Tarallo L.; Giaquinto C.; Ruga E.; Rampon O.; Nogare E.R.D.; Sanfilippo A.; Romano A.; Benaglia G.; Dodi I.; Caselli D.; Maccabruni A.; Pacati I.; Consolini R.; Palla G.; Cecchi M.T.; Vecchi V.; Anzidei G.; Cerilli S.; Chiodi R.; Gattinara G.C.; Krzysztofiak A.; Bernardi S.; Fundar\u00f2 C.; Genovese O.; Colafati G.S.; Catania S.; Ajassa C.; Mazza A.; Garetto S.; Riva C.; Scolfaro C.; Italian Register for HIV Infection in Children and the Italian National AIDS Registry. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000,284(2),190-197","journal-title":"JAMA"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/qjmed\/hcl141","volume":"100","author":"Fang C.T.","year":"2007","unstructured":"Fang C.T.; Chang Y.Y.; Hsu H.M.; Twu S.J.; Chen K.T.; Lin C.C.; Huang L.Y.L.; Chen M.Y.; Hwang J.S.; Wang J.D.; Chuang C.Y.; Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 2007,100(2),97-105","journal-title":"QJM"},{"key":"ref=70","doi-asserted-by":"crossref","DOI":"10.4081\/idr.2013.s1.e5","volume":"5","author":"Pennings P.S.","year":"2013","unstructured":"Pennings P.S.; HIV Drug Resistance: Problems and Perspectives. Infect Dis Rep Available at:2013,5(Suppl. 1)","journal-title":"Infect Dis Rep"},{"key":"ref=71","first-page":"157","volume":"6","author":"Amiji M.M.","year":"2006","unstructured":"Amiji M.M.; Vyas T.K.; Shah L.K.; Role of nanotechnology in HIV\/AIDS treatment: potential to overcome the viral reservoir challenge. Discov Med 2006,6(34),157-162","journal-title":"Discov Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jama.280.1.67","volume":"280","author":"Schrager L.K.","year":"1998","unstructured":"Schrager L.K.; D\u2019Souza M.P.; Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998,280(1),67-71","journal-title":"JAMA"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1146\/annurev.med.53.082901.104024","volume":"53","author":"Blankson J.N.","year":"2002","unstructured":"Blankson J.N.; Persaud D.; Siliciano R.F.; The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002,53,557-593","journal-title":"Annu Rev Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14740338.7.1.1","volume":"7","author":"Tymchuk C.N.","year":"2008","unstructured":"Tymchuk C.N.; Currier J.S.; The safety of antiretroviral drugs. Expert Opin Drug Saf 2008,7(1),1-4","journal-title":"Expert Opin Drug Saf"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2165\/00003088-199936040-00004","volume":"36","author":"Barry M.","year":"1999","unstructured":"Barry M.; Mulcahy F.; Merry C.; Gibbons S.; Back D.; Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999,36(4),289-304","journal-title":"Clin Pharmacokinet"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11587300-000000000-00000","volume":"13","author":"Phelps B.R.","year":"2011","unstructured":"Phelps B.R.; Rakhmanina N.; Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges. Paediatr Drugs 2011,13(3),175-192","journal-title":"Paediatr Drugs"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1086\/378301","volume":"37","author":"Sethi A.K.","year":"2003","unstructured":"Sethi A.K.; Celentano D.D.; Gange S.J.; Moore R.D.; Gallant J.E.; Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003,37(8),1112-1118","journal-title":"Clin Infect Dis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40272-016-0210-4","volume":"19","author":"Dubrocq G.","year":"2017","unstructured":"Dubrocq G.; Rakhmanina N.; Phelps B.R.; Challenges and opportunities in the development of HIV medications in pediatric patients. Paediatr Drugs 2017,19(2),91-98","journal-title":"Paediatr Drugs"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2147\/IJN.S38378","volume":"9","author":"Onoue S.","year":"2014","unstructured":"Onoue S.; Yamada S.; Chan H-K.; Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine 2014,9,1025-1037","journal-title":"Int J Nanomedicine"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1021\/mp800049w","volume":"5","author":"Li S.D.","year":"2008","unstructured":"Li S.D.; Huang L.; Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008,5(4),496-504","journal-title":"Mol Pharm"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.addr.2009.11.017","volume":"62","author":"das Neves J.","year":"2010","unstructured":"das Neves J.; Amiji M.M..; Bahia M.F.; Sarmento B.; Nanotechnology-based systems for the treatment and prevention of HIV\/AIDS. Adv Drug Deliv Rev 2010,62(4-5),458-477","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1517\/17425247.3.5.613","volume":"3","author":"Vyas T.K.","year":"2006","unstructured":"Vyas T.K.; Shah L.; Amiji M.M.; Nanoparticulate drug carriers for delivery of HIV\/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv 2006,3(5),613-628","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2217\/17469600.1.1.49","volume":"1","author":"Shahiwala A.","year":"2007","unstructured":"Shahiwala A.; Amiji M.M.; Nanotechnology-based delivery systems in HIV\/AIDS therapy. Future HIV Ther 2007,1(1),49-59","journal-title":"Future HIV Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jbiotec.2004.06.007","volume":"113","author":"Muller R.H.","year":"2004","unstructured":"Muller R.H.; Keck C.M.; Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004,113(1-3),151-170","journal-title":"J Biotechnol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nano.2005.06.004","volume":"1","author":"Koo O.M.","year":"2005","unstructured":"Koo O.M.; Rubinstein I.; Onyuksel H.; Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 2005,1(3),193-212","journal-title":"Nanomedicine"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.2147\/IJN.S25871","volume":"7","author":"Mahajan S.D.","year":"2012","unstructured":"Mahajan S.D.; Aalinkeel R.; Law W-C.; Reynolds J.L.; Nair B.B.; Sykes D.E.; Yong K-T.; Roy I.; Prasad P.N.; Schwartz S.A.; Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomedicine 2012,7,5301-5314","journal-title":"Int J Nanomedicine"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-642-00477-3_1","volume":"197","author":"Torchilin V.P.","year":"2010","unstructured":"Torchilin V.P.; Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010,197(197),3-53","journal-title":"Handb Exp Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.2217\/nnm.15.160","volume":"10","author":"Roy U.","year":"2015","unstructured":"Roy U.; Rodr\u00edguez J.; Barber P.; das Neves J.; Sarmento B.; Nair M.; The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond) 2015,10(24),3597-3609","journal-title":"Nanomedicine (Lond)"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.addr.2016.02.008","volume":"103","author":"Nair M.","year":"2016","unstructured":"Nair M.; Jayant R.D.; Kaushik A.; Sagar V.; Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev 2016,103,202-217","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.2174\/1381612822666160726113001","volume":"22","author":"Bertrand L.","year":"2016","unstructured":"Bertrand L.; Nair M.; Toborek M.; Solving the blood-brain barrier challenge for the effective treatment of HIV replication in the central nervous system. Curr Pharm Des 2016,22(35),5477-5486","journal-title":"Curr Pharm Des"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11481-017-9725-x","volume":"12","author":"Reynolds J.L.","year":"2017","unstructured":"Reynolds J.L.; Mahato R.I.; Nanomedicines for the treatment of CNS Diseases. J Neuroimmune Pharmacol 2017,12(1),1-5","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1016\/j.xphs.2016.09.015","volume":"105","author":"Kirtane A.R.","year":"2016","unstructured":"Kirtane A.R.; Langer R.; Traverso G.; Past, present, and future drug delivery systems for antiretrovirals. J Pharm Sci 2016,105(12),3471-3482","journal-title":"J Pharm Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/1381612822666151125000550","volume":"22","author":"Baig M.H.","year":"2016","unstructured":"Baig M.H.; Ahmad K.; Roy S.; Ashraf J.M.; Adil M.; Siddiqui M.H.; Khan S.; Kamal M.A.; Provazn\u00edk I.; Choi I.; Computer aided drug design: success and limitations. Curr Pharm Des 2016,22(5),572-581","journal-title":"Curr Pharm Des"},{"key":"ref=94","doi-asserted-by":"publisher","DOI":"10.1088\/1742-6596\/884\/1\/012072","volume":"884","author":"Jain A.","year":"2017","unstructured":"Jain A.; Computer aided drug design. J Phys Conf Ser 2017,884(1)","journal-title":"J Phys Conf Ser"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-4939-7404-7_3","volume":"132","author":"Lemos A.","year":"2018","unstructured":"Lemos A.; Melo R.; Moreira I.S.; Cordeiro M.N.D.S.; Computational Modeling of Drugs Against Alzheimer\u2019s Disease 2018,132,61-106","journal-title":"Computational Modeling of Drugs Against Alzheimer\u2019s Disease"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2174\/1570159X16666180308161642","volume":"16","author":"Lemos A.","year":"2018","unstructured":"Lemos A.; Melo R.; Preto A.J.; Almeida J.G.; Moreira 1.S.; Cordeiro M.N.D.S.; In silico studies targeting Gprotein coupled receptors for drug research against parkinson\u2019s disease. Curr Neuropharmacol 2018,16(6),786-848","journal-title":"Curr Neuropharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.drudis.2010.01.004","volume":"15","author":"Tan J.J.","year":"2010","unstructured":"Tan J.J.; Cong X.J.; Hu L.M.; Wang C.X.; Jia L.; Liang X.J.; Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov Today 2010,15(5-6),186-197","journal-title":"Drug Discov Today"},{"key":"ref=98","doi-asserted-by":"publisher","DOI":"10.5936\/csbj.201302011","volume":"5","author":"Lounnas V.","year":"2013","unstructured":"Lounnas V.; Ritschel T.; Kelder J.; McGuire R.; Bywater R.P.; Foloppe N.; Current progress in structure-based rational drug design marks a new mindset in drug discovery. Comput Struct Biotechnol J 2013,5","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/978-1-62703-398-5_17","volume":"1008","author":"Turnbull A.P.","year":"2013","unstructured":"Turnbull A.P.; Emsley P.; Studying protein-ligand interactions using X-ray crystallography. Methods Mol Biol 2013,1008,457-477","journal-title":"Methods Mol Biol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1110\/ps.062501507","volume":"16","author":"Huang S-Y.","year":"2007","unstructured":"Huang S-Y.; Zou X.; Efficient molecular docking of NMR structures: application to HIV-1 protease. Protein Sci 2007,16(1),43-51","journal-title":"Protein Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"Kitchen D.B.","year":"2004","unstructured":"Kitchen D.B.; Decornez H.; Furr J.R.; Bajorath J.; Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004,3(11),935-949","journal-title":"Nat Rev Drug Discov"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"Meng X-Y.","year":"2011","unstructured":"Meng X-Y.; Zhang H-X.; Mezei M.; Cui M.; Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011,7(2),146-157","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"Ferreira L.G.","year":"2015","unstructured":"Ferreira L.G.; Dos Santos R.N.; Oliva G.; Andricopulo A.D.; Molecular docking and structure-based drug design strategies. Molecules 2015,20(7),13384-13421","journal-title":"Molecules"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/med.21393","volume":"36","author":"Lemos A.","year":"2016","unstructured":"Lemos A.; Le\u00e3o M.; Soares J.; Palmeira A.; Pinto M.; Saraiva L.; Sousa M.E.; Medicinal chemistry strategies to disrupt the p53-MDM2\/MDMX interaction. Med Res Rev 2016,36(5),789-844","journal-title":"Med Res Rev"},{"key":"ref=105","first-page":"845","volume":"83","author":"McConkey B.J.","year":"2002","unstructured":"McConkey B.J.; Sobolev V.; Edelman M.; The performance of current methods in ligand\u2013protein docking. Curr Sci 2002,83(7),845-856","journal-title":"Curr Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"8.14.1","DOI":"10.1002\/0471250953.bi0814s24","volume":"24","author":"Morris G.M.","year":"2008","unstructured":"Morris G.M.; Huey R.; Olson A.J.; Using AutoDock for ligand-receptor docking. Curr Protoc Bioinform 2008,24(1),8.14.1-8.14.40","journal-title":"Curr Protoc Bioinform"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/jcc.10306","volume":"24","author":"Wu G.","year":"2003","unstructured":"Wu G.; Robertson D.H.; Brooks C.L.; Vieth M.; Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 2003,24(13),1549-1562","journal-title":"J Comput Chem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/jcc.23905","volume":"36","author":"Allen W.J.","year":"2015","unstructured":"Allen W.J.; Balius T.E.; Mukherjee S.; Brozell S.R.; Moustakas D.T.; Lang P.T.; Case D.A.; Kuntz I.D.; Rizzo R.C.; DOCK 6: Impact of new features and current docking performance. J Comput Chem 2015,36(15),1132-1156","journal-title":"J Comput Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1023\/A:1008066310669","volume":"13","author":"Makino S.","year":"1999","unstructured":"Makino S.; Ewing T.J.; Kuntz I.D.; DREAM++: flexible docking program for virtual combinatorial libraries. J Comput Aided Mol Des 1999,13(5),513-532","journal-title":"J Comput Aided Mol Des"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1006\/jmbi.1996.0477","volume":"261","author":"Rarey M.","year":"1996","unstructured":"Rarey M.; Kramer B.; Lengauer T.; Klebe G.; A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996,261(3),470-489","journal-title":"J Mol Biol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/prot.10465","volume":"52","author":"Verdonk M.L.","year":"2003","unstructured":"Verdonk M.L.; Cole J.C.; Hartshorn M.J.; Murray C.W.; Taylor R.D.; Improved protein-ligand docking using GOLD. Proteins 2003,52(4),609-623","journal-title":"Proteins"},{"key":"ref=113","doi-asserted-by":"publisher","DOI":"10.1002\/0471250953.bi0812s18","volume":"18","author":"Repasky M.P.","year":"2007","unstructured":"Repasky M.P.; Shelley M.; Friesner R.A.; Flexible ligand docking with Glide. Curr Protoc Bioinformatics 2007,18(1)","journal-title":"Curr Protoc Bioinformatics"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10822-012-9547-0","volume":"26","author":"Neves M.A.","year":"2012","unstructured":"Neves M.A.; Totrov M.; Abagyan R.; Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des 2012,26(6),675-686","journal-title":"J Comput Aided Mol Des"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1021\/ci6004299","volume":"47","author":"Rao S.N.","year":"2007","unstructured":"Rao S.N.; Head M.S.; Kulkarni A.; LaLonde J.M.; Validation studies of the site-directed docking program LibDock. J Chem Inf Model 2007,47(6),2159-2171","journal-title":"J Chem Inf Model"},{"key":"ref=116","doi-asserted-by":"publisher","DOI":"10.1371%2Fjournal.pone.0107837","volume":"9","author":"Bai Q.","year":"2014","unstructured":"Bai Q.; Shao Y.; Pan D.; Zhang Y.; Liu H.; Yao X.; Search for \u03b22 adrenergic receptor ligands by virtual screening via grid computing and investigation of binding modes by docking and molecular dynamics simulations. PLoS One 2014,9(9)","journal-title":"PLoS One"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/ci800298z","volume":"49","author":"Korb O.","year":"2009","unstructured":"Korb O.; St\u00fctzle T.; Exner T.E.; Empirical scoring functions for advanced protein-ligand docking with plants. J Chem Inf Model 2009,49(1),84-96","journal-title":"J Chem Inf Model"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1007\/s00044-011-9720-3","volume":"21","author":"Telvekar V.N.","year":"2012","unstructured":"Telvekar V.N.; Chaudhari H.K.; 3D-QSAR and dockingbased combined in silico study on C-5 methyl substituted 4- arylthio and 4-aryloxy-3-iodopyridin-2-(1H)-one as HIV-1 RT inhibitors. Med Chem Res 2012,21(8),2032-2043","journal-title":"Med Chem Res"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/jmbi.1998.2171","volume":"284","author":"Hsiou Y.","year":"1998","unstructured":"Hsiou Y.; Das K.; Ding J.; Clark A.D.; Kleim J.P.; R\u00f6sner M.; Winkler I.; Riess G.; Hughes S.H.; Arnold E.; Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol 1998,284(2),313-323","journal-title":"J Mol Biol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10822-006-9050-6","volume":"20","author":"Zhang Z.","year":"2006","unstructured":"Zhang Z.; Zheng M.; Du L.; Shen J.; Luo X.; Zhu W.; Jiang H.; Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues. J Comput Aided Mol Des 2006,20(5),281-293","journal-title":"J Comput Aided Mol Des"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1021\/jm2000757","volume":"54","author":"Chung S.","year":"2011","unstructured":"Chung S.; Himmel D.M.; Jiang J-K.; Wojtak K.; Bauman J.D.; Rausch J.W.; Wilson J.A.; Beutler J.A.; Thomas C.J.; Arnold E.; Le Grice S.F.J.; Synthesis, activity, and structural analysis of novel \u03b1-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. J Med Chem 2011,54(13),4462-4473","journal-title":"J Med Chem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1073\/pnas.0711209105","volume":"105","author":"Das K.","year":"2008","unstructured":"Das K.; Bauman J.D.; Clark A.D.; Frenkel Y.V.; Lewi P.J.; Shatkin A.J.; Hughes S.H.; Arnold E.; High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 2008,105(5),1466-1471","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.bmc.2005.11.014","volume":"14","author":"Deng B.L.","year":"2006","unstructured":"Deng B.L.; Cullen M.D.; Zhou Z.; Hartman T.L.; Buckheit R.W.; Pannecouque C.; De Clercq E.; Fanwick P.E.; Cushman M.; Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings. Bioorg Med Chem 2006,14(7),2366-2374","journal-title":"Bioorg Med Chem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nsb0495-293","volume":"2","author":"Ren J.","year":"1995","unstructured":"Ren J.; Esnouf R.; Garman E.; Somers D.; Ross C.; Kirby I.; Keeling J.; Darby G.; Jones Y.; Stuart D.; Stammers D.; High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995,2(4),293-302","journal-title":"Nat Struct Biol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.bmcl.2007.01.025","volume":"17","author":"Barreca M.L.","year":"2007","unstructured":"Barreca M.L.; Rao A.; De Luca L.; Iraci N.; Monforte A.M.; Maga G.; De Clercq E.; Pannecouque C.; Balzarini J.; Chimirri A.; Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem Lett 2007,17(7),1956-1960","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1747-0285.2008.00716.x","volume":"72","author":"Lagos C.F.","year":"2008","unstructured":"Lagos C.F.; Caballero J.; Gonzalez-Nilo F.D.; David Pessoa-Mahana C.; Perez-Acle T.; Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Chem Biol Drug Des 2008,72(5),360-369","journal-title":"Chem Biol Drug Des"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00044-007-9004-0","volume":"15","author":"Boechat N.","year":"2007","unstructured":"Boechat N.; Kover W.B.; Bastos M.M.; Romeiro N.C.; Silva A.S.C.; Santos F.C.; Valverde A.L.; Azevedo M.L.G.; Wollinger W.; Souza T.M.L.; de Souza S.L.O.; de Frugulhetti I.C.P.P.; Design, synthesis, and biological evaluation of new 3-hydroxy-2-oxo-3-trifluoromethylindole as potential HIV-1 reverse transcriptase inhibitors. Med Chem Res 2007,15(9),492-510","journal-title":"Med Chem Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2015.04.050","volume":"97","author":"Wan Z.Y.","year":"2015","unstructured":"Wan Z.Y.; Yao J.; Tao Y.; Mao T.Q.; Wang X.L.; Lu Y.P.; Wang H.F.; Yin H.; Wu Y.; Chen F.E.; De Clercq E.; Daelemans D.; Pannecouque C.; Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem 2015,97,1-9","journal-title":"Eur J Med Chem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1016\/j.bmcl.2010.05.040","volume":"20","author":"Kertesz D.J.","year":"2010","unstructured":"Kertesz D.J.; Brotherton-Pleiss C.; Yang M.; Wang Z.; Lin X.; Qiu Z.; Hirschfeld D.R.; Gleason S.; Mirzadegan T.; Dunten P.W.; Harris S.F.; Villase\u00f1or A.G.; Hang J.Q.; Heilek G.M.; Klumpp K.; Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. Bioorg Med Chem Lett 2010,20(14),4215-4218","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/cbdd.13086","volume":"91","author":"Fan N.","year":"2018","unstructured":"Fan N.; Zhang S.; Sheng T.; Zhao L.; Liu Z.; Liu J.; Wang X.; Docking field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase. Chem Biol Drug Des 2018,91(2),398-407","journal-title":"Chem Biol Drug Des"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1021\/jm960056x","volume":"39","author":"Hopkins A.L.","year":"1996","unstructured":"Hopkins A.L.; Ren J.; Esnouf R.M.; Willcox B.E.; Jones E.Y.; Ross C.; Miyasaka T.; Walker R.T.; Tanaka H.; Stammers D.K.; Stuart D.I.; Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 1996,39(8),1589-1600","journal-title":"J Med Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/cbdd.12397","volume":"85","author":"Singh A.","year":"2015","unstructured":"Singh A.; Yadav D.; Yadav M.; Dhamanage A.; Kulkarni S.; Singh R.K.; Molecular modeling, synthesis and biological evaluation of N-heteroaryl compounds as reverse transcriptase inhibitors against HIV-1. Chem Biol Drug Des 2015,85(3),336-347","journal-title":"Chem Biol Drug Des"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"7449","DOI":"10.1021\/jm800527x","volume":"51","author":"Sweeney Z.K.","year":"2008","unstructured":"Sweeney Z.K.; Harris S.F.; Arora S.F.; Javanbakht H.; Li Y.; Fretland J.; Davidson J.P.; Billedeau J.R.; Gleason S.K.; Hirschfeld D.; Kennedy-Smith J.J.; Mirzadegan T.; Roetz R.; Smith M.; Sperry S.; Suh J.M.; Wu J.; Tsing S.; Villase\u00f1or A.G.; Paul A.; Su G.; Heilek G.; Hang J.Q.; Zhou A.S.; Jernelius J.A.; Zhang F.J.; Klumpp K.; Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. J Med Chem 2008,51(23),7449-7458","journal-title":"J Med Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"7649","DOI":"10.3390\/molecules16097649","volume":"16","author":"Cheng P.","year":"2011","unstructured":"Cheng P.; Gu Q.; Liu W.; Zou J.F.; Ou Y.Y.; Luo Z.Y.; Zeng J.G.; Synthesis of quinolin-2-one alkaloid derivatives and their inhibitory activities against HIV-1 reverse transcriptase. Molecules 2011,16(9),7649-7661","journal-title":"Molecules"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/cbdd.12252","volume":"83","author":"Dineshkumar K.","year":"2014","unstructured":"Dineshkumar K.; Aparna V.; Madhuri K.Z.; Hopper W.; Biological activity of sporolides A and B from Salinispora tropica: in silico target prediction using ligand-based pharmacophore mapping and in vitro activity validation on HIV-1 reverse transcriptase. Chem Biol Drug Des 2014,83(3),350-361","journal-title":"Chem Biol Drug Des"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"7920","DOI":"10.1021\/jm2010173","volume":"54","author":"Gomez R.","year":"2011","unstructured":"Gomez R.; Jolly S.J.; Williams T.; Vacca J.P.; Torrent M.; McGaughey G.; Lai M.T.; Felock P.; Munshi V.; Distefano D.; Flynn J.; Miller M.; Yan Y.; Reid J.; Sanchez R.; Liang Y.; Paton B.; Wan B.L.; Anthony N.; Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase. J Med Chem 2011,54(22),7920-7933","journal-title":"J Med Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"13040","DOI":"10.1073\/pnas.96.23.13040","volume":"96","author":"Goldgur Y.","year":"1999","unstructured":"Goldgur Y.; Craigie R.; Cohen G.H.; Fujiwara T.; Yoshinaga T.; Fujishita T.; Sugimoto H.; Endo T.; Murai H.; Davies D.R.; Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999,96(23),13040-13043","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1007\/s00044-017-1969-8","volume":"26","author":"Safakish M.","year":"2017","unstructured":"Safakish M.; Hajimahdi Z.; Zabihollahi R.; Aghasadeghi M.R.; Vahabpour R.; Zarghi A.; Design, synthesis, and docking studies of new 2-benzoxazolinone derivatives as anti-HIV-1 agents. Med Chem Res 2017,26(11),2718-2726","journal-title":"Med Chem Res"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"20057","DOI":"10.1073\/pnas.1010246107","volume":"107","author":"Hare S.","year":"2010","unstructured":"Hare S.; Vos A.M.; Clayton R.F.; Thuring J.W.; Cummings M.D.; Cherepanov P.; Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA 2010,107(46),20057-20062","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.1016\/j.bmc.2017.09.006","volume":"25","author":"Gao P.","year":"2017","unstructured":"Gao P.; Zhang L.; Sun L.; Huang T.; Tan J.; Zhang J.; Zhou Z.; Zhao T.; Men\u00e9ndez-Arias L.; Pannecouque C.; Clercq E.; Zhan P.; Liu X.; 1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. Bioorg Med Chem 2017,25(20),5779-5789","journal-title":"Bioorg Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/mol.111.073189","volume":"80","author":"Hare S.","year":"2011","unstructured":"Hare S.; Smith S.J.; M\u00e9tifiot M.; Jaxa-Chamiec A.; Pommier Y.; Hughes S.H.; Cherepanov P.; Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572). Mol Pharmacol 2011,80(4),565-572","journal-title":"Mol Pharmacol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejmech.2017.03.059","volume":"133","author":"Tang J.","year":"2017","unstructured":"Tang J.; Vernekar S.K.V.; Chen Y.L.; Miller L.; Huber A.D.; Myshakina N.; Sarafianos S.G.; Parniak M.A.; Wang Z.; Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase. Eur J Med Chem 2017,133,85-96","journal-title":"Eur J Med Chem"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.1128\/JVI.00353-10","volume":"84","author":"Su H.P.","year":"2010","unstructured":"Su H.P.; Yan Y.; Prasad G.S.; Smith R.F.; Daniels C.L.; Abeywickrema P.D.; Reid J.C.; Loughran H.M.; Kornienko M.; Sharma S.; Grobler J.A.; Xu B.; Sardana V.; Allison T.J.; Williams P.D.; Darke P.L.; Hazuda D.J.; Munshi S.; Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol 2010,84(15),7625-7633","journal-title":"J Virol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1007\/s00044-015-1443-4","volume":"24","author":"Rostami M.","year":"2015","unstructured":"Rostami M.; Sirous H.; Zabihollahi R.; Aghasadeghi M.R.; Sadat S.M.; Namazi R.; Saghaie L.; Memarian H.R.; Fassihi A.; Design, synthesis and anti-HIV-1 evaluation of a series of 5-hydroxypyridine-4-one derivatives as possible integrase inhibitors. Med Chem Res 2015,24(12),4113-4127","journal-title":"Med Chem Res"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s00044-016-1772-y","volume":"26","author":"Vyas V.K.","year":"2017","unstructured":"Vyas V.K.; Shah S.; Ghate M.; Generation of new leads as HIV-1 integrase inhibitors: 3D QSAR, docking and molecular dynamics simulation. Med Chem Res 2017,26(3),532-550","journal-title":"Med Chem Res"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"S1081","DOI":"10.1016\/j.arabjc.2013.01.015","volume":"10","author":"Srivastav V.K.","year":"2017","unstructured":"Srivastav V.K.; Tiwari M.; QSAR and docking studies of coumarin derivatives as potent HIV-1 integrase inhibitors. Arab J Chem 2017,10,S1081-S1094","journal-title":"Arab J Chem"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"27594","DOI":"10.1039\/C6RA00713A","volume":"6","author":"Han D.","year":"2016","unstructured":"Han D.; Su M.; Tan J.; Li C.; Zhang X.; Wang C.; Structure- activity relationship and binding mode studies for a series of diketo-acids as HIV integrase inhibitors by 3DQSAR, molecular docking and molecular dynamics simulations. RSC Advances 2016,6(33),27594-27606","journal-title":"RSC Advances"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1087057112465979","volume":"18","author":"Wielens J.","year":"2013","unstructured":"Wielens J.; Headey S.J.; Rhodes D.I.; Mulder R.J.; Dolezal O.; Deadman J.J.; Newman J.; Chalmers D.K.; Parker M.W.; Peat T.S.; Scanlon M.J.; Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J Biomol Screen 2013,18(2),147-159","journal-title":"J Biomol Screen"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/cbdd.12974","volume":"90","author":"Debnath U.","year":"2017","unstructured":"Debnath U.; Kumar P.; Agarwal A.; Kesharwani A.; Gupta S.K.; Katti S.B.; N-hydroxy-substituted 2-aryl acetamide analogs: a novel class of HIV-1 integrase inhibitors. Chem Biol Drug Des 2017,90(4),527-534","journal-title":"Chem Biol Drug Des"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bmc.2014.12.059","volume":"23","author":"Wang Y.","year":"2015","unstructured":"Wang Y.; Rong J.; Zhang B.; Hu L.; Wang X.; Zeng C.; Design and synthesis of N-methylpyrimidone derivatives as HIV-1 integrase inhibitors. Bioorg Med Chem 2015,23(4),735-741","journal-title":"Bioorg Med Chem"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejmech.2016.04.019","volume":"117","author":"Patel S.B.","year":"2016","unstructured":"Patel S.B.; Patel B.D.; Pannecouque C.; Bhatt H.G.; Design, synthesis and anti-HIV activity of novel quinoxaline derivatives. Eur J Med Chem 2016,117,230-240","journal-title":"Eur J Med Chem"},{"key":"ref=152","doi-asserted-by":"publisher","DOI":"10.1002\/cem.2934","volume":"31","author":"Jianbo T.","year":"2017","unstructured":"Jianbo T.; Pei Z.; Simon W.X.; Yingji W.; Quionolone carboxylic acid derivatives as HIV1 integrase inhibitors: Docking based HQSAR and topomer CoMFA analyses. J Chemometr 2017,31(12)","journal-title":"J Chemometr"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1128\/JVI.01829-15","volume":"90","author":"Aoki M.","year":"2015","unstructured":"Aoki M.; Hayashi H.; Yedidi R.S.; Martyr C.D.; Takamatsu Y.; Aoki-Ogata H.; Nakamura T.; Nakata H.; Das D.; Yamagata Y.; Ghosh A.K.; Mitsuya H.; C-5-modified tetrahydropyrano-tetrahydofuran-derived protease inhibitors (PIs) exert potent inhibition of the replication of HIV-1 variants highly resistant to various PIs, including Darunavir. J Virol 2015,90(5),2180-2194","journal-title":"J Virol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/08927022.2015.1067808","volume":"42","author":"Sroczynski D.","year":"2016","unstructured":"Sroczynski D.; Malinowski Z.; Szczesniak A.K.; Pakulska W.; New 1-(2H)-phthalazinone derivatives as potent nonpeptidic HIV-1 protease inhibitors: molecular docking studies, molecular dynamics simulation, oral bioavailability and ADME prediction. Mol Simul 2016,42(8),628-641","journal-title":"Mol Simul"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1007\/s00044-014-0992-2","volume":"23","author":"Nunthanavanit P.","year":"2014","unstructured":"Nunthanavanit P.; Ungwitayatorn J.; Molecular docking studies of chromone derivatives against wild type and mutant strains of HIV-1 protease. Med Chem Res 2014,23(9),4198-4208","journal-title":"Med Chem Res"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1021\/jm960588d","volume":"40","author":"B\u00e4ckbro K.","year":"1997","unstructured":"B\u00e4ckbro K.; L\u00f6wgren S.; Osterlund K.; Atepo J.; Unge T.; Hult\u00e9n J.; Bonham N.M.; Schaal W.; Karl\u00e9n A.; Hallberg A.; Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J Med Chem 1997,40(6),898-902","journal-title":"J Med Chem"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jmb.2005.09.095","volume":"354","author":"Liu F.","year":"2005","unstructured":"Liu F.; Boross P.I.; Wang Y.F.; Tozser J.; Louis J.M.; Harrison R.W.; Weber I.T.; Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol 2005,354(4),789-800","journal-title":"J Mol Biol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1021\/bi962234u","volume":"36","author":"Ala P.J.","year":"1997","unstructured":"Ala P.J.; Huston E.E.; Klabe R.M.; McCabe D.D.; Duke J.L.; Rizzo C.J.; Korant B.D.; DeLoskey R.J.; Lam P.Y.; Hodge C.N.; Chang C.H.; Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 1997,36(7),1573-1580","journal-title":"Biochemistry"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/j.1432-1033.2004.04060.x","volume":"271","author":"Mahalingam B.","year":"2004","unstructured":"Mahalingam B.; Wang Y.F.; Boross P.I.; Tozser J.; Louis J.M.; Harrison R.W.; Weber I.T.; Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur J Biochem 2004,271(8),1516-1524","journal-title":"Eur J Biochem"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1107\/S0907444900000469","volume":"56","author":"Munshi S.","year":"2000","unstructured":"Munshi S.; Chen Z.; Yan Y.; Li Y.; Olsen D.B.; Schock H.B.; Galvin B.B.; Dorsey B.; Kuo L.C.; An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. Acta Crystallogr D Biol Crystallogr 2000,56(Pt 4),381-388","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"12141","DOI":"10.1021\/bi049459m","volume":"43","author":"Clemente J.C.","year":"2004","unstructured":"Clemente J.C.; Moose R.E.; Hemrajani R.; Whitford L.R.; Govindasamy L.; Reutzel R.; McKenna R.; Agbandje-McKenna M.; Goodenow M.M.; Dunn B.M.; Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. Biochemistry 2004,43(38),12141-12151","journal-title":"Biochemistry"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nsmb1068","volume":"13","author":"Eakin C.M.","year":"2006","unstructured":"Eakin C.M.; Berman A.J.; Miranker A.D.; A native to amyloidogenic transition regulated by a backbone trigger. Nat Struct Mol Biol 2006,13(3),202-208","journal-title":"Nat Struct Mol Biol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molstruc.2016.09.052","volume":"1129","author":"Tong J.","year":"2017","unstructured":"Tong J.; Wu Y.; Bai M.; Zhan P.; 3D-QSAR and molecular docking studies on HIV protease inhibitors. J Mol Struct 2017,1129,17-22","journal-title":"J Mol Struct"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ejmech.2015.06.054","volume":"101","author":"Wei Y.","year":"2015","unstructured":"Wei Y.; Li J.; Chen Z.; Wang F.; Huang W.; Hong Z.; Lin J.; Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods. Eur J Med Chem 2015,101,409-418","journal-title":"Eur J Med Chem"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1021\/cb300191k","volume":"7","author":"King N.M.","year":"2012","unstructured":"King N.M.; Prabu-Jeyabalan M.; Bandaranayake R.M.; Nalam M.N.; Nalivaika E.A.; \u00d6zen A.; Halilo\u011flu T.; Yilmaz N.K.; Schiffer C.A.; Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease. ACS Chem Biol 2012,7(9),1536-1546","journal-title":"ACS Chem Biol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.molstruc.2017.03.029","volume":"1139","author":"Mohammadi A.A.","year":"2017","unstructured":"Mohammadi A.A.; Taheri S.; Amouzegar A.; Ahdenov R.; Halvagar M.R.; Sadr A.S.; Diastereoselective synthesis and molecular docking studies of novel fused tetrahydropyridine derivatives as new inhibitors of HIV protease. J Mol Struct 2017,1139,166-174","journal-title":"J Mol Struct"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1021\/jm00115a028","volume":"34","author":"Krohn A.","year":"1991","unstructured":"Krohn A.; Redshaw S.; Ritchie J.C.; Graves B.J.; Hatada M.H.; Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem 1991,34(11),3340-3342","journal-title":"J Med Chem"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.molstruc.2016.05.065","volume":"1121","author":"Sethuvasan S.","year":"2016","unstructured":"Sethuvasan S.; Sugumar P.; Ponnuswamy M.N.; Ponnuswamy S.; N-Benzyl-2,7-diphenyl-1,4-diazepan-5-one analogues: Synthesis, spectral characterization, stereochemistry, crystal structure and molecular docking studies. J Mol Struct 2016,1121,215-225","journal-title":"J Mol Struct"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/157016306780136781","volume":"3","author":"Bacilieri M.","year":"2006","unstructured":"Bacilieri M.; Moro S.; Ligand-based drug design methodologies in drug discovery process: an overview. Curr Drug Discov Technol 2006,3(3),155-165","journal-title":"Curr Drug Discov Technol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/0929867043456287","volume":"11","author":"Dror O.","year":"2004","unstructured":"Dror O.; Shulman-Peleg A.; Nussinov R.; Wolfson H.J.; Predicting molecular interactions in silico: a guide to pharmacophore identification and its applications to drug design. Curr Med Chem 2004,11(1),71-90","journal-title":"Curr Med Chem"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","volume":"15","author":"Yang S-Y.","year":"2010","unstructured":"Yang S-Y.; Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 2010,15(11-12),444-450","journal-title":"Drug Discov Today"},{"key":"ref=172","author":"Golender V.","year":"1995","unstructured":"Golender V.; Vesterman B.; Eliyahu O.; Kardash A.; Kletzin M.; Shokhen M.; Vorpagel E.; Knowledge engineering approach to drug design and its implementation in the APEX-3D Expert System Proceedings of the 10th European Symposium on Structure-Activity Relationships, QSAR and Molecular Modeling 1995","journal-title":"Proceedings of the 10th European Symposium on Structure-Activity Relationships, QSAR and Molecular Modeling"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1023\/A:1021954728347","volume":"16","author":"Patel Y.","year":"2002","unstructured":"Patel Y.; Gillet V.J.; Bravi G.; Leach A.R.; A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J Comput Aided Mol Des 2002,16(8-9),653-681","journal-title":"J Comput Aided Mol Des"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1021\/ci049885e","volume":"45","author":"Wolber G.","year":"2005","unstructured":"Wolber G.; Langer T.; LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005,45(1),160-169","journal-title":"J Chem Inf Model"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1021\/ci800130k","volume":"48","author":"Chen I-J.","year":"2008","unstructured":"Chen I-J.; Foloppe N.; Conformational sampling of druglike molecules with MOE and catalyst: implications for pharmacophore modeling and virtual screening. J Chem Inf Model 2008,48(9),1773-1791","journal-title":"J Chem Inf Model"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/S0968-0896(00)00185-1","volume":"8","author":"Harris D.L.","year":"2000","unstructured":"Harris D.L.; Loew G.; Development and assessment of a 3D pharmacophore for ligand recognition of BDZR\/GABAA receptors initiating the anxiolytic response. Bioorg Med Chem 2000,8(11),2527-2538","journal-title":"Bioorg Med Chem"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10822-006-9087-6","volume":"20","author":"Dixon S.L.","year":"2006","unstructured":"Dixon S.L.; Smondyrev A.M.; Knoll E.H.; Rao S.N.; Shaw D.E.; Friesner R.A.; PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: methodology and preliminary results. J Comput Aided Mol Des 2006,20(10-11),647-671","journal-title":"J Comput Aided Mol Des"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/jcc.540100804","volume":"10","author":"Clark M.","year":"1989","unstructured":"Clark M.; Cramer R.D.; Van Opdenbosch N.; Validation of the general purpose Tripos 5.2 force field. J Comput Chem 1989,10(8),982-1012","journal-title":"J Comput Chem"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/A:1011102129244","volume":"15","author":"Mills J.E.","year":"2001","unstructured":"Mills J.E.; de Esch I.J.; Perkins T.D.J.; Dean P.M.; SLATE: a method for the superposition of flexible ligands. J Comput Aided Mol Des 2001,15(1),81-96","journal-title":"J Comput Aided Mol Des"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejmech.2012.01.056","volume":"50","author":"Distinto S.","year":"2012","unstructured":"Distinto S.; Esposito F.; Kirchmair J.; Cardia M.C.; Gaspari M.; Maccioni E.; Alcaro S.; Markt P.; Wolber G.; Zinzula L.; Tramontano E.; Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. Eur J Med Chem 2012,50,216-229","journal-title":"Eur J Med Chem"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1021\/ci600320q","volume":"47","author":"Barreca M.L.","year":"2007","unstructured":"Barreca M.L.; De Luca L.; Iraci N.; Rao A.; Ferro S.; Maga G.; Chimirri A.; structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J Chem Inf Model 2007,47(2),557-562","journal-title":"J Chem Inf Model"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S1093-3263(02)00183-3","volume":"21","author":"Keller P.A.","year":"2003","unstructured":"Keller P.A.; Birch C.; Leach S.P.; Tyssen D.; Griffith R.; Novel pharmacophore-based methods reveal gossypol as a reverse transcriptase inhibitor. J Mol Graph Model 2003,21(5),365-373","journal-title":"J Mol Graph Model"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11094-011-0556-4","volume":"45","author":"Rani P.","year":"2011","unstructured":"Rani P.; Kumar V.; Development of pharmacophore models for predicting HIV-1 reverse transcriptase inhibitory activity of pyridinone derivatives. Pharm Chem J 2011,45(1),36-42","journal-title":"Pharm Chem J"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/1062936X.2013.772919","volume":"24","author":"Reddy K.K.","year":"2013","unstructured":"Reddy K.K.; Singh S.K.; Tripathi S.K.; Selvaraj C.; Identification of potential HIV-1 integrase strand transfer inhibitors: in silico virtual screening and QM\/MM docking studies. SAR QSAR Environ Res 2013,24(7),581-595","journal-title":"SAR QSAR Environ Res"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cbi.2014.04.011","volume":"218","author":"Reddy K.K.","year":"2014","unstructured":"Reddy K.K.; Singh S.K.; Combined ligand and structure-based approaches on HIV-1 integrase strand transfer inhibitors. Chem Biol Interact 2014,218,71-81","journal-title":"Chem Biol Interact"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/1062936X.2013.792870","volume":"24","author":"Sangeetha B.","year":"2013","unstructured":"Sangeetha B.; Muthukumaran R.; Amutha R.; Pharmacophore modelling and electronic feature analysis of hydroxamic acid derivatives, the HIV integrase inhibitors. SAR QSAR Environ Res 2013,24(9),753-771","journal-title":"SAR QSAR Environ Res"},{"key":"ref=187","volume":"7","author":"Yadav D.","year":"2012","unstructured":"Yadav D.; Paliwal S.; Yadav R.; Pal M.; Pandey A.; Identification of novel HIV 1-protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening. PLoS One 2012,7(11)","journal-title":"PLoS One"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.chemolab.2016.03.017","volume":"154","author":"Ravichandran V.","year":"2016","unstructured":"Ravichandran V.; Venkateskumar K.; Shalini S.; Harish R.; Exploring the structure\u2013activity relationship of oxazolidinones as HIV-1 protease inhibitors - QSAR and pharmacophore modelling studies. Chemom Intell Lab Syst 2016,154,52-61","journal-title":"Chemom Intell Lab Syst"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1897\/01-171","volume":"22","author":"Perkins R.","year":"2003","unstructured":"Perkins R.; Fang H.; Tong W.; Welsh W.J.; Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem 2003,22(8),1666-1679","journal-title":"Environ Toxicol Chem"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/138620706776055539","volume":"9","author":"Dudek A.Z.","year":"2006","unstructured":"Dudek A.Z.; Arodz T.; G\u00e1lvez J.; Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb Chem High Throughput Screen 2006,9(3),213-228","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1021\/jm4004285","volume":"57","author":"Cherkasov A.","year":"2014","unstructured":"Cherkasov A.; Muratov E.N.; Fourches D.; Varnek A.; Baskin I.I.; Cronin M.; Dearden J.; Gramatica P.; Martin Y.C.; Todeschini R.; Consonni V.; Kuz\u2019min V.E.; Cramer R.; Benigni R.; Yang C.; Rathman J.; Terfloth L.; Gasteiger J.; Richard A.; Tropsha A.; QSAR modeling: where have you been? Where are you going to? J Med Chem 2014,57(12),4977-5010","journal-title":"J Med Chem"},{"key":"ref=192","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-17281-1","author":"Roy K.","year":"2015","unstructured":"Roy K.; Kar S.; Das R.N.; A primer on QSAR\/QSPR modeling 2015","journal-title":"A primer on QSAR\/QSPR modeling"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1021\/ja00226a005","volume":"110","author":"Cramer R.D.","year":"1988","unstructured":"Cramer R.D.; Patterson D.E.; Bunce J.D.; Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988,110(18),5959-5967","journal-title":"J Am Chem Soc"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/9783527618279.ch44d","author":"Kubinyi H.","year":"2008","unstructured":"Kubinyi H.; Handbook of Chemoinformatics: From Data to Knowledge in 4 Volumes 2008,1555-1574","journal-title":"Handbook of Chemoinformatics: From Data to Knowledge in 4 Volumes"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1021\/jm00050a010","volume":"37","author":"Klebe G.","year":"1994","unstructured":"Klebe G.; Abraham U.; Mietzner T.; Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994,37(24),4130-4146","journal-title":"J Med Chem"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"7738","DOI":"10.1016\/j.bmc.2007.08.060","volume":"15","author":"Moda T.L.","year":"2007","unstructured":"Moda T.L.; Montanari C.A.; Andricopulo A.D.; Hologram QSAR model for the prediction of human oral bioavailability. Bioorg Med Chem 2007,15(24),7738-7745","journal-title":"Bioorg Med Chem"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/cbdd.12917","volume":"89","author":"Heidari A.","year":"2017","unstructured":"Heidari A.; Fatemi M.H.; Comparative molecular field analysis (CoMFA), topomer CoMFA, and hologram QSAR studies on a series of novel HIV-1 protease inhibitors. Chem Biol Drug Des 2017,89(6),918-931","journal-title":"Chem Biol Drug Des"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.1016\/j.bmcl.2004.09.068","volume":"14","author":"Balaji S.","year":"2004","unstructured":"Balaji S.; Karthikeyan C.; Moorthy N.S.; Trivedi P.; QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of PVSA and pharmacophore feature descriptors. Bioorg Med Chem Lett 2004,14(24),6089-6094","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ejmech.2010.12.022","volume":"46","author":"Vadivelan S.","year":"2011","unstructured":"Vadivelan S.; Deeksha T.N.; Arun S.; Machiraju P.K.; Gundla R.; Sinha B.N.; Jagarlapudi S.A.R.P.; Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads. Eur J Med Chem 2011,46(3),851-859","journal-title":"Eur J Med Chem"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2306\/scienceasia1513-1874.2004.30.081","volume":"30","author":"Samee W.","year":"2010","unstructured":"Samee W.; Ungwitayatorn J.; Matayatsuk C.; Pimthon J.; 3D-QSAR studies on phthalimide derivatives as HIV-1 reverse transcriptase inhibitors. Sci Asia 2010,30,81-88","journal-title":"Sci Asia"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1007\/s00044-015-1381-1","volume":"24","author":"Liu X.","year":"2015","unstructured":"Liu X.; Chen X.; Zhang L.; Zhan P.; Liu X.; 3D-QSAR and docking studies on piperidine-substituted diarylpyrimidine analogues as HIV-1 reverse transcriptase inhibitors. Med Chem Res 2015,24(8),3314-3326","journal-title":"Med Chem Res"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jtice.2015.07.024","volume":"59","author":"Patel S.","year":"2016","unstructured":"Patel S.; Patel B.; Bhatt H.; 3D-QSAR studies on 5- hydroxy-6-oxo-1,6-dihydropyrimidine-4- carboxamide derivatives as HIV-1 integrase inhibitors. J Taiwan Inst Chem Eng 2016,59,61-68","journal-title":"J Taiwan Inst Chem Eng"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.arabjc.2011.03.006","volume":"9","author":"Ghasemi G.","year":"2016","unstructured":"Ghasemi G.; Nirouei M.; Shariati S.; Abdolmaleki P.; Rastgoo Z.; A quantitative structure\u2013activity relationship study on HIV-1 integrase inhibitors using genetic algorithm, artificial neural networks and different statistical methods. Arab J Chem 2016,9(Suppl. 1),S185-S190","journal-title":"Arab J Chem"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ardp.200700229","volume":"341","author":"Nunthanavanit P.","year":"2008","unstructured":"Nunthanavanit P.; Anthony N.G.; Johnston B.F.; Mackay S.P.; Ungwitayatorn J.; 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis. Arch Pharm (Weinheim) 2008,341(6),357-364","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/1062936X.2017.1388281","volume":"28","author":"Bhargava S.","year":"2017","unstructured":"Bhargava S.; Adhikari N.; Amin S.A.; Das K.; Gayen S.; Jha T.; Hydroxyethylamine derivatives as HIV-1 protease inhibitors: a predictive QSAR modelling study based on Monte Carlo optimization. SAR QSAR Environ Res 2017,28(12),973-990","journal-title":"SAR QSAR Environ Res"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/qsar.200730051","volume":"27","author":"Ioakimidis L.","year":"2008","unstructured":"Ioakimidis L.; Thoukydidis L.; Mirza A.; Naeem S.; Reynisson J.; Benchmarking the reliability of QikProp. Correlation between experimental and predicted values. QSAR Comb Sci 2008,27(4),445-456","journal-title":"QSAR Comb Sci"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/2211352512666141021002621","volume":"13","author":"Yadav G.","year":"2015","unstructured":"Yadav G.; Ganguly S.; Murugesan S.; Dev A.; Synthesis, anti-HIV, antimicrobial evaluation and structure activity relationship studies of some novel benzimidazole derivatives. Antiinfect Agents 2015,13(1),65-77","journal-title":"Antiinfect Agents"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1007\/s00044-012-0463-6","volume":"22","author":"Kashid A.M.","year":"2013","unstructured":"Kashid A.M.; Dube P.N.; Alkutkar P.G.; Bothara K.G.; Mokale S.N.; Dhawale S.C.; Synthesis, biological screening and ADME prediction of benzylindole derivatives as novel anti-HIV-1, anti-fungal and anti-bacterial agents. Med Chem Res 2013,22(10),4633-4640","journal-title":"Med Chem Res"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00044-010-9329-y","volume":"20","author":"Pawar V.S.","year":"2011","unstructured":"Pawar V.S.; Lokwani D.K.; Bhandari S.V.; Bothara K.G.; Chitre T.S.; Devale T.L.; Modhave N.S.; Parikh J.K.; Design, docking study and ADME prediction of Isatin derivatives as anti-HIV agents. Med Chem Res 2011,20(3),370-380","journal-title":"Med Chem Res"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1016\/j.bmc.2010.03.030","volume":"18","author":"Pawar V.","year":"2010","unstructured":"Pawar V.; Lokwani D.; Bhandari S.; Mitra D.; Sabde S.; Bothara K.; Madgulkar A.; Design of potential reverse transcriptase inhibitor containing Isatin nucleus using molecular modeling studies. Bioorg Med Chem 2010,18(9),3198-3211","journal-title":"Bioorg Med Chem"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11030-012-9417-7","volume":"17","author":"Belekar V.","year":"2013","unstructured":"Belekar V.; Shah A.; Garg P.; High-throughput virtual screening of phloroglucinol derivatives against HIV-reverse transcriptase. Mol Divers 2013,17(1),97-110","journal-title":"Mol Divers"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1007\/s00044-011-9940-6","volume":"21","author":"Tripathi S.K.","year":"2012","unstructured":"Tripathi S.K.; Selvaraj C.; Singh S.K.; Reddy K.K.; Molecular docking, QPLD, and ADME prediction studies on HIV-1 integrase leads. Med Chem Res 2012,21(12),4239-4251","journal-title":"Med Chem Res"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jmgm.2008.06.006","volume":"27","author":"Frecer V.","year":"2008","unstructured":"Frecer V.; Berti F.; Benedetti F.; Miertus S.; Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties. J Mol Graph Model 2008,27(3),376-387","journal-title":"J Mol Graph Model"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1747-0285.2012.01326.x","volume":"79","author":"Gupta P.","year":"2012","unstructured":"Gupta P.; Garg P.; Roy N.; Identification of novel HIV-1 integrase inhibitors using shape-based screening, QSAR, and docking approach. Chem Biol Drug Des 2012,79(5),835-849","journal-title":"Chem Biol Drug Des"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00894-009-0636-5","volume":"16","author":"Khedkar V.M.","year":"2010","unstructured":"Khedkar V.M.; Ambre P.K.; Verma J.; Shaikh M.S.; Pissurlenkar R.R.; Coutinho E.C.; Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors. J Mol Model 2010,16(7),1251-1268","journal-title":"J Mol Model"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1570162043351327","volume":"2","author":"Markovic I.","year":"2004","unstructured":"Markovic I.; Clouse K.A.; Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2004,2(3),223-234","journal-title":"Curr HIV Res"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2009.07.022","volume":"85","author":"Tilton J.C.","year":"2010","unstructured":"Tilton J.C.; Doms R.W.; Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 2010,85(1),91-100","journal-title":"Antiviral Res"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"13235","DOI":"10.1128\/JVI.00204-07","volume":"81","author":"Mehle A.","year":"2007","unstructured":"Mehle A.; Wilson H.; Zhang C.; Brazier A.J.; McPike M.; Pery E.; Gabuzda D.; Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 2007,81(23),13235-13241","journal-title":"J Virol"},{"key":"ref=219","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/649315","volume":"2010649315","author":"Cadima-Couto I.","year":"2010","unstructured":"Cadima-Couto I.; Goncalves J.; Towards inhibition of Vif-APOBEC3G interaction: which protein to target? Adv Virol 2010,2010649315","journal-title":"Adv Virol"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature03493","volume":"435","author":"Chiu Y-L.","year":"2005","unstructured":"Chiu Y-L.; Soros V.B.; Kreisberg J.F.; Stopak K.; Yonemoto W.; Greene W.C.; Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005,435(7038),108-114","journal-title":"Nature"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.tig.2006.05.006","volume":"22","author":"Ciuffi A.","year":"2006","unstructured":"Ciuffi A.; Bushman F.D.; Retroviral DNA integration: HIV and the role of LEDGF\/p75. Trends Genet 2006,22(7),388-395","journal-title":"Trends Genet"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00018-008-7540-5","volume":"65","author":"Poeschla E.M.","year":"2008","unstructured":"Poeschla E.M.; Integrase, LEDGF\/p75 and HIV replication. Cell Mol Life Sci 2008,65(9),1403-1424","journal-title":"Cell Mol Life Sci"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.virol.2012.09.033","volume":"435","author":"Christ F.","year":"2013","unstructured":"Christ F.; Debyser Z.; The LEDGF\/p75 integrase interaction, a novel target for anti-HIV therapy. Virology 2013,435(1),102-109","journal-title":"Virology"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/prot.22399","volume":"76","author":"Di Fenza A.","year":"2009","unstructured":"Di Fenza A.; Rocchia W.; Tozzini V.; Complexes of HIV-1 integrase with HAT proteins: multiscale models, dynamics, and hypotheses on allosteric sites of inhibition. Proteins 2009,76(4),946-958","journal-title":"Proteins"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1128\/JVI.02061-08","volume":"83","author":"Woodward C.L.","year":"2009","unstructured":"Woodward C.L.; Prakobwanakit S.; Mosessian S.; Chow S.A.; Integrase interacts with nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus type 1. J Virol 2009,83(13),6522-6533","journal-title":"J Virol"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"R710","DOI":"10.1016\/j.cub.2008.07.037","volume":"18","author":"Luban J.","year":"2008","unstructured":"Luban J.; HIV-1 infection: going nuclear with TNPO3\/Transportin-SR2 and integrase. Curr Biol 2008,18(16),R710-R713","journal-title":"Curr Biol"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2217\/17469600.1.4.415","volume":"1","author":"Engelman A.","year":"2007","unstructured":"Engelman A.; Host cell factors and HIV-1 integration. Future HIV Ther 2007,1(4),415-426","journal-title":"Future HIV Ther"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/17584310.3.2.171","volume":"3","author":"Thys W.","year":"2009","unstructured":"Thys W.; Busschots K.; McNeely M.; Voet A.; Christ F.; Debyser Z.; LEDGF\/p75 and transportin-SR2 are cellular cofactors of HIV integrase and novel targets for antiviral therapy. HIV Ther 2009,3(2),171-188","journal-title":"HIV Ther"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.2174\/1381612823666170704130635","volume":"23","author":"Rice A.P.","year":"2017","unstructured":"Rice A.P.; The HIV-1 Tat protein: mechanism of action and target for HIV-1 cure strategies. Curr Pharm Des 2017,23(28),4098-4102","journal-title":"Curr Pharm Des"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/01.COH.0000239851.22614.6a","volume":"1","author":"Daelemans D.","year":"2006","unstructured":"Daelemans D.; Pannecouque C.; HIV-1 Rev function as target for antiretroviral drug development. Curr Opin HIV AIDS 2006,1(5),388-397","journal-title":"Curr Opin HIV AIDS"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14728222.5.1.1","volume":"5","author":"Coleman S.H.","year":"2001","unstructured":"Coleman S.H.; Day J.R.; Guatelli J.C.; The HIV-1 Nef protein as a target for antiretroviral therapy. Expert Opin Ther Targets 2001,5(1),1-22","journal-title":"Expert Opin Ther Targets"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1016\/j.ddtec.2013.07.002","volume":"10","author":"Smithgall T.E.","year":"2013","unstructured":"Smithgall T.E.; Thomas G.; Small molecule inhibitors of the HIV-1 virulence factor, Nef. Drug Discov Today Technol 2013,10(4),e523-e529","journal-title":"Drug Discov Today Technol"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1742-4690-8-25","volume":"8","author":"Kogan M.","year":"2011","unstructured":"Kogan M.; Rappaport J.; HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 2011,8,25","journal-title":"Retrovirology"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/ijms18010126","volume":"18","author":"Gonz\u00e1lez M.E.","year":"2017","unstructured":"Gonz\u00e1lez M.E.; The HIV-1 Vpr Protein: A multifaceted target for therapeutic intervention. Int J Mol Sci 2017,18(1),126","journal-title":"Int J Mol Sci"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/viro.1998.9398","volume":"251","author":"Freed E.O.","year":"1998","unstructured":"Freed E.O.; HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998,251(1),1-15","journal-title":"Virology"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1083\/jcb.200302138","volume":"162","author":"Pornillos O.","year":"2003","unstructured":"Pornillos O.; Higginson D.S.; Stray K.M.; Fisher R.D.; Garrus J.E.; Payne M.; He G-P.; Wang H.E.; Morham S.G.; Sundquist W.I.; HIV Gag mimics the Tsg101-recruiting activity of the human Hrs protein. J Cell Biol 2003,162(3),425-434","journal-title":"J Cell Biol"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0966-842X(02)00013-6","volume":"11","author":"Freed E.O.","year":"2003","unstructured":"Freed E.O.; The HIV-TSG101 interface: recent advances in a budding field. Trends Microbiol 2003,11(2),56-59","journal-title":"Trends Microbiol"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.2174\/092986710793176357","volume":"17","author":"Zhan P.","year":"2010","unstructured":"Zhan P.; Li W.; Chen H.; Liu X.; Targeting protein-protein interactions: a promising avenue of anti-HIV drug discovery. Curr Med Chem 2010,17(29),3393-3409","journal-title":"Curr Med Chem"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbadis.2009.12.003","volume":"1802","author":"Arhel N.","year":"2010","unstructured":"Arhel N.; Kirchhoff F.; Host proteins involved in HIV infection: new therapeutic targets. Biochim Biophys Acta 2010,1802(3),313-321","journal-title":"Biochim Biophys Acta"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1039\/C0CS00092B","volume":"40","author":"Tavassoli A.","year":"2011","unstructured":"Tavassoli A.; Targeting the protein-protein interactions of the HIV lifecycle. Chem Soc Rev 2011,40(3),1337-1346","journal-title":"Chem Soc Rev"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/165112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:46:45Z","timestamp":1693874805000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/165112\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":240,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666180904123549","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}